Replies to post #340021 on Avid Bioservices Inc (CDMO)

[swg_tdr]

Endo, b4 patents expire, CA may have a significant earthquake.

[Protector]

EndoTarget, CDMO could produce it with agreement of HALO.

But customer, when patent protection ends, do not need to ASK HALO anymore.

CDMO could produce it at the same terms as Generic Manufacturers with that difference that CDMO is up and running.

BP will never turn to generic manufacturers, they certainly don't want them to get revenue to make even more generic products.

And BP holds the right to the combination products anyway. The recombinant on its own is worthless.